Elanco Animal Health Incorporated Interest Expense
Elanco Animal Health Incorporated (ELAN) reported Interest Expense of $58.00 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2024-11-07
- Elanco Animal Health Incorporated interest expense for the quarter ending 2024-09-30 was $58.00M, a 19.44% decline year-over-year.
- Elanco Animal Health Incorporated interest expense for the quarter ending 2024-06-30 was $65.00M, a 12.16% decline year-over-year.
- Elanco Animal Health Incorporated interest expense for the quarter ending 2024-03-31 was $66.00M, a 3.13% increase year-over-year.
- Elanco Animal Health Incorporated interest expense for the quarter ending 2023-12-31 was $67.00M, a 8.06% increase year-over-year.
- Elanco Animal Health Incorporated interest expense for fiscal 2023 was $277.00M, a 14.94% increase from fiscal 2022.
- Elanco Animal Health Incorporated interest expense for fiscal 2022 was $241.00M, a 2.12% increase from fiscal 2021.
- Elanco Animal Health Incorporated interest expense for fiscal 2021 was $236.00M, a 57.33% increase from fiscal 2020.
- Elanco Animal Health Incorporated interest expense for fiscal 2020 was $150.00M, a 89.87% increase from fiscal 2019.
| Period end | Interest Expense 3 month | Interest Expense 3 month as first filed | Interest Expense 6 month | Interest Expense 6 month as first filed | Interest Expense 9 month | Interest Expense 9 month as first filed | Interest Expense 12 month | Interest Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | $58.00M 10-Q · filed 2024-11-07 | $123.00M derived: sum of 2 quarters · filed 2024-11-07 | $189.00M 10-Q · filed 2024-11-07 | $256.00M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2024-06-30 | $65.00M 10-Q · filed 2024-08-08 | $131.00M 10-Q · filed 2024-08-08 | $198.00M derived: sum of 3 quarters · filed 2024-08-08 | $270.00M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2024-03-31 | $66.00M 10-Q · filed 2024-05-08 | $133.00M derived: sum of 2 quarters · filed 2024-05-08 | $205.00M derived: sum of 3 quarters · filed 2024-11-07 | $279.00M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-12-31 | $67.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $139.00M derived: sum of 2 quarters · filed 2024-11-07 | $213.00M derived: sum of 3 quarters · filed 2024-11-07 | $277.00M 10-K · filed 2024-02-26 | ||||
| 2023-09-30 | $72.00M 10-Q · filed 2024-11-07 | $146.00M derived: sum of 2 quarters · filed 2024-11-07 | $210.00M 10-Q · filed 2024-11-07 | $272.00M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $74.00M 10-Q · filed 2024-08-08 | $138.00M 10-Q · filed 2024-08-08 | $200.00M derived: sum of 3 quarters · filed 2024-08-08 | $260.00M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | $64.00M 10-Q · filed 2024-05-08 | $126.00M derived: sum of 2 quarters · filed 2024-05-08 | $186.00M derived: sum of 3 quarters · filed 2024-05-08 | $253.00M derived: sum of 4 quarters · filed 2024-05-08 | ||||
| 2022-12-31 | $62.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $122.00M derived: sum of 2 quarters · filed 2024-02-26 | $189.00M derived: sum of 3 quarters · filed 2024-02-26 | $241.00M 10-K · filed 2024-02-26 | ||||
| 2022-09-30 | $60.00M 10-Q · filed 2023-11-07 | $127.00M derived: sum of 2 quarters · filed 2023-11-07 | $179.00M 10-Q · filed 2023-11-07 | $234.00M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-06-30 | $67.00M 10-Q · filed 2023-08-07 | $119.00M 10-Q · filed 2023-08-07 | $174.00M derived: sum of 3 quarters · filed 2024-02-26 | $234.00M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-03-31 | $52.00M 10-Q · filed 2023-05-09 | $107.00M derived: sum of 2 quarters · filed 2024-02-26 | $167.00M derived: sum of 3 quarters · filed 2024-02-26 | $227.00M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2021-12-31 | $55.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $115.00M derived: sum of 2 quarters · filed 2024-02-26 | $175.00M derived: sum of 3 quarters · filed 2024-02-26 | $236.00M 10-K · filed 2024-02-26 | ||||
| 2021-09-30 | $60.00M 10-Q · filed 2022-11-08 | $120.00M derived: sum of 2 quarters · filed 2023-03-01 | $181.00M 10-Q · filed 2022-11-08 | $241.40M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-06-30 | $60.00M 10-K · filed 2023-03-01 | $121.00M 10-Q · filed 2022-08-08 | $181.40M derived: sum of 3 quarters · filed 2023-03-01 | $229.40M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-03-31 | $61.00M 10-K · filed 2023-03-01 | $121.40M derived: sum of 2 quarters · filed 2023-03-01 | $169.40M derived: sum of 3 quarters · filed 2023-03-01 | $194.40M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2020-12-31 | $60.40M 10-K · filed 2021-03-01 | $108.40M derived: sum of 2 quarters · filed 2021-11-05 | $133.40M derived: sum of 3 quarters · filed 2021-11-05 | $150.00M 10-K · filed 2023-03-01 | $149.80M 10-K · filed 2021-03-01 | |||
| 2020-09-30 | $48.00M 10-Q · filed 2021-11-05 | $48.10M 10-Q · filed 2020-11-06 | $73.00M derived: sum of 2 quarters · filed 2021-11-05 | $89.00M 10-Q · filed 2021-11-05 | $89.40M 10-Q · filed 2020-11-06 | $107.70M derived: sum of 4 quarters · filed 2021-11-05 | ||
| 2020-06-30 | $25.00M 10-Q · filed 2021-08-09 | $24.80M 10-Q · filed 2020-07-30 | $41.00M 10-Q · filed 2021-08-09 | $41.30M 10-Q · filed 2020-07-30 | $59.70M derived: sum of 3 quarters · filed 2021-08-09 | $78.40M derived: sum of 4 quarters · filed 2021-08-09 | ||
| 2020-03-31 | $16.00M 10-Q · filed 2021-05-07 | $16.50M 10-Q · filed 2020-05-07 | $34.70M derived: sum of 2 quarters · filed 2021-05-07 | $53.40M derived: sum of 3 quarters · filed 2021-05-07 | $74.10M derived: sum of 4 quarters · filed 2021-05-07 | |||
| 2019-12-31 | $18.70M 10-K · filed 2021-03-01 | $37.40M derived: sum of 2 quarters · filed 2021-03-01 | $58.10M derived: sum of 3 quarters · filed 2021-03-01 | $79.00M 10-K · filed 2022-02-28 | $78.90M 10-K · filed 2020-02-28 | |||
| 2019-09-30 | $18.70M 10-Q · filed 2020-11-06 | $39.40M derived: sum of 2 quarters · filed 2020-11-06 | $60.20M 10-Q · filed 2020-11-06 | $81.20M derived: sum of 4 quarters · filed 2020-11-06 | ||||
| 2019-06-30 | $20.70M 10-Q · filed 2020-07-30 | $41.50M 10-Q · filed 2020-07-30 | $62.50M derived: sum of 3 quarters · filed 2020-07-30 | $71.10M derived: sum of 4 quarters · filed 2020-07-30 | ||||
| 2019-03-31 | $20.80M 10-Q · filed 2020-05-07 | $41.80M derived: sum of 2 quarters · filed 2020-05-07 | $50.40M derived: sum of 3 quarters · filed 2020-05-07 | $50.40M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | $21.00M 10-K · filed 2020-02-28 | $29.60M derived: sum of 2 quarters · filed 2020-02-28 | $29.60M derived: sum of 3 quarters · filed 2020-02-28 | $29.60M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | $8.60M 10-K · filed 2020-02-28 | $8.60M derived: sum of 2 quarters · filed 2020-02-28 | $8.60M 10-Q · filed 2019-11-08 | $8.60M derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2018-06-30 | $0.00 10-K · filed 2020-02-28 | $0.00 10-Q · filed 2019-08-13 | $0.00 derived: sum of 3 quarters · filed 2020-02-28 | $0.00 derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2018-03-31 | $0.00 10-K · filed 2020-02-28 | $0.00 derived: sum of 2 quarters · filed 2020-02-28 | $0.00 derived: sum of 3 quarters · filed 2020-02-28 | $0.00 derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2017-12-31 | $0.00 10-K · filed 2019-02-20 | $0.00 derived: sum of 2 quarters · filed 2019-02-20 | $0.00 derived: sum of 3 quarters · filed 2019-02-20 | $0.00 10-K · filed 2020-02-28 | ||||
| 2017-09-30 | $0.00 10-K · filed 2019-02-20 | $0.00 derived: sum of 2 quarters · filed 2019-02-20 | $0.00 derived: sum of 3 quarters · filed 2019-02-20 | |||||
| 2017-06-30 | $0.00 10-K · filed 2019-02-20 | $0.00 derived: sum of 2 quarters · filed 2019-02-20 | ||||||
| 2017-03-31 | $0.00 10-K · filed 2019-02-20 | |||||||
| 2016-12-31 | $0.00 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |